Secondary prevention of atherosclerotic cardiovascular disease

Secondary prevention of atherosclerotic cardiovascular disease refers to clinical management aimed at reducing the risk of recurrent major adverse cardiovascular events and mortality in individuals with established, clinically evident vascular disease

Secondary prevention of atherosclerotic cardiovascular disease refers to clinical management aimed at reducing the risk of recurrent major adverse cardiovascular events and mortality in individuals with established, clinically evident vascular disease Pathophysiologically, it addresses chronic systemic fibrofatty plaque accumulation, vascular inflammation, and endothelial dysfunction in arterial walls, where subsequent plaque rupture or erosion precipitates acute luminal thrombosis and tissue is...

This indication encompasses patients who have documented conditions across the vascular system, including a history of acute coronary syndrome, myocardial infarction, stable or unstable angina, prior coronary or peripheral arterial revascularization, ischemic stroke, transient ischemic attack, or peripheral artery disease Therapeutic goals focus on aggressive risk factor modification to halt plaque progression, stabilize existing lesions, and prevent subsequent cardiovascular morbidity

This indication encompasses patients who have documented conditions across the vascular system, including a history of acute coronary syndrome, myocardial infarction, stable or unstable angina, prior coronary or peripheral arterial revascularization, ischemic stroke, transient ischemic attack, or peripheral artery disease

Pathophysiologically, it addresses chronic systemic fibrofatty plaque accumulation, vascular inflammation, and endothelial dysfunction in arterial walls, where subsequent plaque rupture or erosion precipitates acute luminal thrombosis and tissue ischemia